文献速递膀胱癌与上尿路尿路上皮癌

八十岁以上器官局限性尿路上皮膀胱癌患者三联治疗后的生存分析

Survival after trimodal therapy in octogenarians with organ-confined urothelial bladder cancer.
PubMed 文献 · BJU Int · 2024-12-12

该研究基于监测、流行病学和最终结果数据库(2004-2021年),比较八十岁以上器官局限性(T2N0M0)尿路上皮膀胱癌患者接受三联治疗(TMT)与根治性膀胱切除术(RC)后的癌症特异性死亡率(CSM)。结果显示TMT使用率从2004年的53.5%升至2021年的82.2%(P<0.001),但TMT组的5年CSM为50.1%,RC组为31.1%;多因素竞争风险回归和倾向性评分匹配后,TMT均独立预测CSM升高1.7倍(P<0.001)。

要点

  • 八十岁以上T2N0M0尿路上皮膀胱癌患者中,TMT使用率从2004年53.5%增至2021年82.2%(P<0.001)。
  • TMT组5年癌症特异性死亡率为50.1%,RC组为31.1%。
  • 多因素竞争风险回归和倾向性评分匹配后,TMT均独立预测CSM升高1.7倍(P<0.001)。

核心结论

  • 近年八十岁以上器官局限性尿路上皮膀胱癌患者中TMT使用率几乎翻倍,但TMT后的癌症特异性死亡率也几乎为RC后的两倍,传达这些观察结果至关重要。

研究设计与样本

  • 基于监测、流行病学和最终结果数据库(2004-2021年)的队列研究,纳入2335例八十岁以上T2N0M0尿路上皮膀胱癌患者,其中1562例(66.3%)接受TMT,793例(33.7%)接受RC;2082例(88.4%)为白人。

主要发现

  • TMT使用率从2004年的53.5%上升至2021年的82.2%(P<0.001)。
  • 5年癌症特异性死亡率为TMT组50.1% vs RC组31.1%。
  • 多因素竞争风险回归中,TMT独立预测癌症特异性死亡风险升高1.7倍(P<0.001)。
  • 倾向性评分匹配后,TMT仍独立预测癌症特异性死亡风险升高1.7倍(P<0.001)。
  • 仅限白人患者的敏感性分析结果几乎相同。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: It is not known whether cancer-specific mortality (CSM) differences distinguish radical cystectomy (RC) from trimodal therapy (TMT) in octogenarians harbouring organ-confined (T2N0M0) urothelial cancer of the urinary bladder (UCUB). METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2021), CSM and other-cause mortality (OCM) rates were computed in octogenarian patients with organ-confined UCUB undergoing either TMT or RC. Smoothed cumulative incidence plots depicted 5-year CSM and OCM rates according to RC vs TMT. Competing risks regression (CRR) models were fitted, adjusting for age, gender, and race/ethnicity. Nearest-neighbour 1:1 propensity-score matching (PSM) for age and gender was also applied. Sensitivity analyses were additionally performed, focusing on White patients. RESULTS: Of 2335 octogenarian patients with T2N0M0 UCUB, 1562 (66.3%) received TMT and 793 (33.7%) received RC. Of those, 2082 (88.4%) were White. TMT rates increased from 53.5% in 2004 to 82.2% in 2021 (P < 0.001). The 5-year CSM rate was 50.1% for TMT vs 31.1% for RC. After multivariable CRR, TMT independently predicted 1.7-fold higher CSM (P < 0.001). After additional PSM, TMT also independently predicted 1.7-fold higher CSM (P < 0.001). In sensitivity analyses exclusively focusing on White patients, almost identical results were recorded. CONCLUSION: Rates of TMT have nearly doubled in octogenarian patients with organ-confined UCUB in recent years; however, CSM rates after TMT are also nearly twice as high as those observed after RC. It is crucial to communicate these observations.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Longoni M, Di Bello F, Rodriguez Peñaranda N, et al. Survival after trimodal therapy in octogenarians with organ-confined urothelial bladder cancer. BJU Int. 2024. PMID: 39667393. doi:10.1111/bju.16622

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。